Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: A retrospective study of physician-patient pairs in Taiwan
- 30 November 2009
- journal article
- research article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 31 (11), 2618-2627
- https://doi.org/10.1016/j.clinthera.2009.11.022
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education
This publication has 22 references indexed in Scilit:
- Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxibArthritis Care & Research, 2008
- Evaluation of Risk Profiles for Gastrointestinal and Cardiovascular Adverse Effects in Nonselective NSAID and COX-2 Inhibitor UsersDrug Safety, 2008
- What happened to the prescribing of other COX‐2 inhibitors, paracetamol and non‐steroidal anti‐inflammatory drugs when rofecoxib was withdrawn in Australia?Pharmacoepidemiology and Drug Safety, 2007
- Cardiovascular events associated with the use of four nonselective NSAIDs (Etodolac, Nabumetone, Ibuprofen, or Naproxen) Versus a Cyclooxygenase-2 Inhibitor (Celecoxib): A population-based analysis in taiwanese adultsClinical Therapeutics, 2006
- Use of cyclo‐oxygenase 2 inhibitors (COX‐2) and prescription non‐steroidal anti‐inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX‐2 cardiovascular profilePharmacoepidemiology and Drug Safety, 2006
- NSAID‐induced gastrointestinal damage: Current clinical management and recommendations for preventionChinese Journal of Digestive Diseases, 2006
- Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: What is the potential impact of the withdrawal of rofecoxib?Arthritis Care & Research, 2006
- Cardiovascular Events Associated with Long-Term Use of Celecoxib, Rofecoxib and Meloxicam in TaiwanDrug Safety, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialThe New England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionThe New England Journal of Medicine, 2005